May 29, 2026 Release Highlights Copied

Practice Insights announces the implementation of technical fixes within the application to support Merit-Based Incentive Payment System (MIPS) requirements.

Performance Improvements

We’ve optimized the following Dashboard to improve speed and usability:

1. NCCN Distress Thermometer Dashboard
2. EOM Eligibility Dashboard
3. VBC Navigation Summary Dashboard

What this means for your practice

• Faster dashboard load times
• Quicker navigation and data access
• A smoother day-to-day experience

Most practices should see the dashboard load about twice as fast as before.

MIPS Quality Measures Dashboard

The MIPS Quality Measures Dashboard will be updated to reflect the below refinement(s):

Measure	Update	Practice Impact
PIMSH 19: Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents – Avoidance of Overuse (Inverse Measure)	Denominator Updates Added inclusion of intravenous and oral antineoplastic agent combinations to both Denominator 1 and Denominator 2 Denominator Exceptions Added: Rate 1 Patients prescribed olanzapine as a PRN order Patients prescribed olanzapine for other indications Rate 2 Patients prescribed a 5-HT3 RA, dexamethasone, or olanzapine as a PRN order Patients prescribed olanzapine or dexamethasone for other indications Patients whose antineoplastic regimen includes dexamethasone Medication List Updates Intravenous & Oral antineoplastic agents list has been updated to reflect additions and removals Benchmark Scoring New first year Measure standard with a 7-point scoring floor	New Measure (Rewrite of PIMSH 15)
PIMSH 20: Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents	Denominator Updates Added inclusion of intravenous and oral antineoplastic agent combinations to both Denominator 1 and Denominator 2 Denominator Exceptions Added Denominator 1 & Denominator 2 Patients whose antineoplastic regimen includes prednisone Medication List Updates Intravenous & Oral antineoplastic agents list has been updated to reflect additions and removals New first year Measure standard with a 7-point scoring floor	New Measure (Rewrite of PIMSH 16)

EOM Performance Dashboard

The EOM Performance Measures Dashboard will be updated to reflect the following:

Measure	Update	Practice Impact
EOM-5: Preventive Care Screening: Screening for Depression and Follow-Up Plan	Denominator Update Added 2 new CPT codes 59425 59426	Practices will not notice a shift in data.

Advance Care Planning Dashboards

You can view the final data from Q1 2026 using the Time Period drop-down on the Advance Care Planning Performance and Advance Care Planning Activities dashboards.

Status of Dashboard Updates for 2026

CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. Ontada will continue to notify practices once measures have been updated based on the current 2026 requirements.

The following measures have been fully updated for the 2026 measure year:

Measure Number	Description
MIPS Quality Measures Dashboard
MIPS #001	Diabetes Hemoglobin A1c (HbA1cc) Poor Control (>9%) (Inverse Measure)
MIPS #047	Advance Care Plan
MIPS #134	Preventive Care Screening: Screening for Depression and Follow-Up Plan
MIPS #143	Pain Intensity Quantified
MIPS #144	Pain Care Plan
MIPS #226	Tobacco Screening and Cessation
MIPS #236	Controlling High Blood Pressure
MIPS #238	Use of High-Risk Medications in Older Adults (Inverse Measure)
MIPS#450	Appropriate Treatment for Patients with Stage I (T1c)-III HER2 Positive Breast Cancer
MIPS #453	Proportion Receiving Chemotherapy in the Last 14 Days of Life (Inverse Measure)
MIPS #457	Proportion Admitted in Hospice for Less Than 3 Days (Inverse Measure)
MIPS #462	Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy
PIMSH #10	Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs
PIMSH #17	Utilization of Prophylactic GCSF for Cancer Patients Receiving Low-Risk Chemotherapy (Inverse Measure)
PIMSH #19	Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents – Avoidance of Overuse (Inverse Measure)
PIMSH #20	PIMSH 20: Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents
PIMSH #21	Screening and Achieving Resolution or Improvement of Distress for Cancer Care
EOM Performance Measures Dashboard
EOM-4A	Pain Intensity Quantified
EOM-4B	Pain Care Plan
EOM-5	Preventive Care Screening: Screening for Depression and Follow-Up Plan